Home Procurement NewsJ&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

January 8, 2024•

The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.

Was this article helpful?

YesNo

Last modified: January 8, 2024

Previous: EFCC detains ex-humanitarian affairs minister over alleged N37.1 billion fraud

Next: Dangote regains top spot from Rupert on Forbes Africa’s billionaire list

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

The articles and content featured on this platform are sourced from various contributors and do not necessarily reflect the views or positions of Accountability Lab Nigeria. We do not author or edit the published materials. If you have concerns about any content or would like to request its removal, please contact us at @Accountability Lab Nigeria.

Recent Posts

Recent Comments

No comments to show.

Are you ready to join the Community?

Join the Conversation!

Community of Practice Portal aims to bring together key stakeholders in the procurement landscape in Nigeria to leverage on each others skillset in relation to understanding Procurement data in a bid to use these data to create stories and to generate action from the government.

Community of practice platform is an initiative under Anti-Corruption Innovation Project, a UNDP funded Project in collaboration with Accountability lab Nigeria, and Open Contracting Partnerships

Accountability Lab Nigeria

Copyright © 2021 - Accountability Lab Nigeria

↑

Close